Rheumatoid arthritis and pregnancy: Impediments to optimal management of both biologic use before, during and after pregnancy

Current Opinion in Rheumatology

Volumn 26, Issue 3, 2014, Pages 341-346

  Williams, Marvin ^a   Chakravarty, Eliza F ^b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

biologic therapy; birth defects; factor inhibitors; pregnancy; rheumatoid arthritis; rituximab; tumour necrosis

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; IMMUNOGLOBULIN FC FRAGMENT; INFLIXIMAB; LIVE VACCINE; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR ALPHA;

BIRTH DEFECT; CONCEPTION; CYTOPENIA; DISEASE ACTIVITY; DRUG EXPOSURE; FETOMATERNAL TRANSFUSION; FETUS CIRCULATION; FIRST TRIMESTER PREGNANCY; GASTROENTEROLOGY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION SENSITIVITY; LOW BIRTH WEIGHT; MYCOBACTERIUM BOVIS BCG; ORGANOGENESIS; PERINATAL MORTALITY; PREGNANCY; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL CARE; PRENATAL PERIOD; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; RISK FACTOR; SECOND TRIMESTER PREGNANCY; TERATOGENICITY; THIRD TRIMESTER PREGNANCY; VACCINATION; ABNORMALITIES, DRUG-INDUCED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; FEMALE; MATERNAL CARE; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE; PROCEDURES;

ABNORMALITIES, DRUG-INDUCED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; FEMALE; HUMANS; MATERNAL-FETAL EXCHANGE; PRECONCEPTION CARE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PRENATAL EXPOSURE DELAYED EFFECTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84897517707     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000046     Document Type: Review

References (28)

1. Corsello G, Giuffrè M. Congenital malformations. J Matern Fetal Neonatal Med 2012; 25 (Suppl 1):25-29.
2. Center for Disease Control and Prevention (CDC). 2013. http://www. cdc.gov/ncbddd/birthdefects/index.html. [Accessed on 2 November, 2004]
3. Chambers C, Scialli A. Teratogenesis and environmental exposure. In: Creasy R, Resnik R, Iams J, Lockwood C, Moore T, Greene M, editors. Creasy & Resnick's maternal fetal medicine principles and practices, 7th ed. St Louis, MO: Saunders; 2014. pp. 465-472.
4. Blackburn ST. Pharmacology and pharmacokinetics during the perinatal period. In: Maternal, fetal, & neonatal physiology: a clinical perspective. 4th ed. Maryland Heights, MO: Saunders; 2013:; pp. 183-202.
5. Millsop JW, Heller MM, Murase JE. Safety classification systems used in dermatological medication risk counseling of pregnant and lactating patients: a case for an evidencebased approach. Dermatol Ther 2013; 26:347-353.
6. Chakravarty EF. T2T: don't forget pregnant patients. Rheumatologists 2012; 6:21-25.
7. Carey JC,Martinez L, Balken E, et al. Determination of human teratogenicity by the astute clinician method: review of illustrative agents and a proposal of guidelines. Birth Defects Res A Clin Mol Teratol 2009; 85:63-68.
8. Parisi MA, Spong CY, Zajicek A, Guttmacher AE. We don't know what we don't study: the case for research on medication effects in pregnancy. Am J Med Genet C Semin Med Genet 2011; 157C:247-250.
9. Carter JD, Ladhani A, Ricca LR, et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 2009; 36:635-641.
10. Koren G, Inoue M. Do tumor necrosis factor inhibitors cause malformations in humans? J Rheumatol 2009; 36:465-466.
11. Raja H, Matteson EL, Michet CJ, et al. Safety of tumor necrosis factor inhibitors during pregnancy and breastfeeding. Transl Vis Sci Technol 2012; 1:6.
12. Barbhaiya M, Bermas BL. Evaluation and management of systemic lupus erythematosus and rheumatoid arthritis during pregnancy. Clin Immunol 2013; 149:225-235.
13. de Man YA, Dolhain JEM, van de Geijn FE, et al. Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum 2008; 59:1241-1248.
14. De Man YA, Hazes JM, van der Heide H, et al. Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results from a national prospective registry. Arthritis Rheum 2009; 60:3196-3206.
15. Chakravarty EF. Rheumatoid arthritis and pregnancy: beyond smaller and preterm babies. Arthritis Rheum 2011; 63:1469-1471.
16. Langen ES, Chakravarty EF, Liaquat M, et al. High rate of preterm birth in pregnancies complicated by rheumatoid arthritis. Am J Perinatol 2014; 31:9-14.
17. Wallenius M, Skomsvoll JF, Irgens LM, et al. Pregnancy and delivery in women with chronic inflammatory arthritides with a specific focus on first birth. Arthritis Rheum 2011; 63:1534-1542.
18. Chambers CD, Johnson DL. Emerging data on the use of antitumor necrosis factor-alpha medications in pregnancy. Birth Defects Res A Clin Mol Teratol 2012; 94:607-611.
19. Palmeira P, Quinello C, Silveira-Lessa AL, et al. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012; 2012: 985646.
20. Simister NE. Placental transport of immunoglobulin G. Vaccine 2003; 21:3365-3369.
21. Nielsen OH, Loftus EV Jr, Jess T. Safety of TNF-a inhibitors during IBD pregnancy: a systematic review. BMC Med 2013; 11:174.
22. Mahadevan U, Martin CF, Sandler RS, et al. PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Updated presentation at the DDW 2012. Gastroenterology 2012; 142:S149.
23. Viktil KK, Engeland A, Furu K. Outcomes after antirheumatoid drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers. Scand J Rheumatol 2012; 41:196-201.
24. Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, Ornoy A. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. Reprod Toxicol 2014; 43:78-84.
25. Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood 2011; 117:1499-1506.
26. Martinez-Martinez MU, Baranda-Candido L, Gonzalez-Amaro R, et al. Modified neonatal B-cell repertoire as a consequence of rituximab administration to a pregnant woman. Rheumatology 2013; 52:405-406.
27. Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of antitumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11:286-292.
28. Cheent K, Nolan J, Sariq S, et al. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's Disease. J Crohns Colitis 2010; 4:603-605.